Translational repression of CYP3A genes, by the pro-inflammatory cytokine interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) have been suggested as the mechanisms causing decreased CYP3A-activity in cancer patients [27,30]. This evidence concerns the gene IL6 and cancer.